discriminating ability of each risk calculator was assessed and compared using the concordance index (cindex). The mean patient age was 67 yr. A positive cancer outcome was present in 46 of 107 men, with only 19 of 107 scheduled for a repeat biopsy. Ultimately, 97 patients were assessed because 10 patients were excluded from the comparison data set due to inconclusive PCA3 assay scores (2 of 10) and patient age <55 yr (8 of 10).
The (Fig. 1) .
The Chun nomogram outperformed the other calculators assessed. Because the initial development of the Chun nomogram involved multiple centres in Europe and included both Canada and the United States [4] , our findings may further support the universality of this PCA3-incorporated risk calculator.
The PCPT risk calculators do not have a specific option within the racial category for the local black African man, so the option other was used for this racial group. This may have underestimated the risk for a certain racial subset in our study and may explain the poorer performance of the PCPT and updated PCPT risk calculators.
Because the ERSPC risk calculator also performed exceptionally well, the cost-benefit ratio of incorporating the PCA3 assay into a risk calculator may be questioned. The role of a more recent PCA3-incorporated, initial-biopsy-specific nomogram [7] may be of added value within the initial biopsy subset of patients in our context. Further evaluation in this regard is needed. For now, the PCA3-incorporated Chun nomogram has outperformed other risk calculators in this setting.
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